Search | Clinical Trials Finder

Conditions: Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions: Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 17 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions: AU-011, Suprachoroidal Microinjector, PDT Laser; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Edematous, Synovitis, Foreign Body Reaction, Osteolysis
Interventions: Placebo, Apatone®B; Drug
Lead sponsor: IC-MedTech Corporation; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Healthy
Interventions: testosterone; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Fort Myers, Florida • Miramar, Florida • Overland Park, Kansas + 1 more

Conditions: Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
Interventions: ONCR-177, pembrolizumab; Biological
Lead sponsor: Oncorus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 6 more

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Matched Placebo, CELLECTRA™-5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more

Conditions: Allergy, Peanut
Interventions: DBV712, Placebo; Drug · Other
Lead sponsor: DBV Technologies; Industry
Eligibility: 4 Years to 7 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: Merkel Cell Carcinoma
Interventions: Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS); Biological · Device
Lead sponsor: OncoSec Medical Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neonatal Abstinence Syndrome, Aromatherapy
Interventions: lavender and chamomile essential oils; Drug
Lead sponsor: John M. Daniel; Other
Eligibility: Up to 2 Weeks
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Low or Intermediate Risk Prostate Cancer
Interventions: MR guided Linear Accelerator; Radiation
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Colorectal Neoplasms
Interventions: Indigo carmine, water (exchange) method, water (exchange) plus dye method, air method; Drug · Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hypogonadism
Interventions: Nasobol®, Androderm® (Positive Control); Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more

Conditions: Cow's Milk Allergy
Interventions: DBV1605; Combination Product
Lead sponsor: DBV Technologies; Industry
Eligibility: 29 Days to 24 Months
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more

Conditions: Hot Flashes
Interventions: Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 45
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more

Conditions: Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions: Tofacitinib ointment; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tobacco Use Cessation
Interventions: Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"; Drug · Genetic · Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atrial Fibrillation
Interventions: Atrial Fibrillation Ablation; Procedure
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years to 85 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Coronary Stenosis
Interventions: TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more

Conditions: ALK-positive Non-small Cell Lung Cancer
Interventions: Ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • South Bend, Indiana + 4 more

Conditions: Basal Cell Carcinoma
Interventions: ALA, PDT; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Port-Wine Stain
Interventions: Cutera excel V™ Laser; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Cessation, Tobacco Use Disorder, Nicotine Dependence, Smokeless Tobacco Use
Interventions: QuitAid (pharmacist-delivered MTM), Nicotine Replacement Therapy (NRT); Behavioral · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Smoking Cessation, Nicotine Dependence
Interventions: Nicotine Replacement Treatment (NRT), varenicline, Behavioral counseling for smoking cessation; Drug · Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Smoking, Tobacco
Interventions: Counseling, Nicotine patch, Community Resource; Behavioral · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 642 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • Newton, Massachusetts • Oak Bluffs, Massachusetts + 1 more

Search by objective public record fields.

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements

Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer

The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels

Phase I Study MR-guided SBRT to PCa

Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

PRecision Interventions for SMoking in the SCCS

Comparing Surgical Management Methods of Atrial Fibrillation

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Pilot Study to Evaluate the Effect of Multiple Passes on Port Wine Stain Treatments With the Cutera Excel V™ Laser.

Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)